Saturday 17 October 2026
Export MDWD’s income statement to Excel — free account
MediWound Ltd.
MDWD Healthcare Biotechnology
MediWound Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.0 million, down 16.1% from fiscal 2024. In the quarter to June 2026, revenue fell 45.8%, EPS grew 53.7%, free cash flow fell 49.9% and total debt rose 51.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
11.85
0.36
−2.95%
Follow MDWD
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.23 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
5 | 2 | 2 | 4 | 4 | 2 | 7 | 4 | 5 | 4 |
P/S ratio |
12.38 | 8.77 | 5.43 | 2.50 | 2.71 | 4.63 | 2.65 | 32.38 | 42.56 | 73.69 |
Altman Z-Score |
(1.05) | (1.57) | (2.01) | (2.88) | (9.36) | (3.09) | (0.45) | (2.00) | (2.28) | (2.92) |
Altman Z″-Score (non-manufacturers) |
(6.94) | (7.81) | (6.05) | (7.35) | (27.13) | (11.97) | (4.65) | (7.30) | (5.99) | (8.09) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.31 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
(3.69) | (3.23) | (0.95) | (1.21) | (3.85) | (2.68) | 4.34 | (0.82) | (2.94) | — |
P/Operating CF |
(69.64) | (108.30) | (38.77) | 33.14 | (28.77) | (30.36) | (36.72) | (54.87) | (24.12) | (27.14) |
P/B ratio |
4.81 | 5.69 | 3.21 | 6.07 | 0.00 | 13.85 | 5.56 | 12.27 | 11.04 | 14.78 |
Price to Tangible BV |
4.82 | 5.71 | 3.23 | 6.20 | 0.00 | 14.58 | 5.72 | 12.99 | 11.82 | 16.41 |
EV/Sales |
9.30 | 6.66 | 3.31 | 1.24 | 2.27 | 3.66 | 1.74 | 25.47 | 28.17 | 54.51 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.82 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(9.79) | (9.89) | (5.91) | (2.77) | (6.04) | (11.56) | 6.68 | (7.13) | (4.27) | (5.16) |
EV/FCF |
(7.28) | (6.76) | (3.64) | (2.64) | (5.70) | (10.14) | 7.43 | (6.81) | (4.00) | (4.91) |
Quick Ratio |
2.17 | 1.86 | 2.58 | 3.64 | 1.28 | 3.00 | 3.28 | 6.34 | 7.30 | 6.09 |
Current Ratio |
2.33 | 1.97 | 2.74 | 3.80 | 1.39 | 3.17 | 3.43 | 6.68 | 7.64 | 6.25 |
Net Debt/EBITDA |
2.27 | 2.41 | 2.98 | 4.79 | 1.11 | 2.79 | (5.22) | 6.99 | 2.75 | 1.53 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.21 | 0.29 | 0.32 | 0.76 | 0.94 | 0.61 | 0.84 | 0.09 | 0.06 | 0.04 |
Operating CF/Net income |
0.68 | 0.45 | 1.56 | 0.61 | 0.66 | 0.75 | 1.67 | 11.50 | 0.74 | 0.87 |
Capex/Depreciation |
(2.96) | (4.23) | (4.96) | (0.44) | (0.39) | (0.85) | (0.69) | (0.93) | (1.90) | (1.19) |
Interest Coverage |
(10.27) | (1.51) | (8.08) | (0.72) | (4.85) | (6.91) | 1.51 | (1.87) | (10.93) | (22.49) |
| (63.86%) | (96.33%) | (31.60%) | (619.05%) | (1,007.51%) | (81.96%) | 41.05% | (11.37%) | (254.73%) | (120.90%) | |
| (29.90%) | (43.19%) | (11.53%) | (56.19%) | (53.34%) | (25.67%) | 13.06% | (2.66%) | (55.44%) | (42.78%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(45.14%) | (76.03%) | (16.46%) | (54.22%) | (201.98%) | (44.73%) | 17.98% | (3.54%) | (58.27%) | (64.00%) |
Average Days of Receivables |
58.78 | 113.89 | 100.42 | 137.51 | 41.56 | 54.16 | 52.32 | 794.18 | 521.32 | 641.68 |
Research and Development Expense of Revenue |
84.44% | 43.90% | 39.96% | 38.42% | 43.16% | 35.37% | 15.63% | 119.73% | 218.83% | 453.66% |
Selling, General and Administrative Expense of Revenue |
83.81% | 64.97% | 62.14% | 40.18% | 40.97% | 39.92% | 29.27% | 234.84% | 366.31% | 801.48% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 |
Share Based Compensation of Revenue |
18.33% | 15.52% | 10.38% | 7.34% | 7.04% | 6.07% | 3.88% | 18.97% | 54.61% | 203.53% |
Graham Net Nets |
0.08 | 0.06 | 0.15 | 0.10 | (0.15) | 0.02 | 0.12 | 0.06 | 0.07 | 0.05 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 9.53 | 0.00 | 10.52 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(11.38%) | (17.25%) | (6.84%) | (28.89%) | (20.76%) | (8.92%) | 5.80% | (0.98%) | (21.53%) | (16.38%) |
Free Cash Flow Yield |
(10.32%) | (11.25%) | (16.74%) | (18.83%) | (14.69%) | (7.80%) | 8.85% | (11.55%) | (16.56%) | (15.06%) |
Revenue per Share |
1.49 | 2.03 | 2.07 | 5.31 | 6.11 | 5.60 | 8.18 | 0.88 | 0.75 | 0.50 |
Operating CF per Share |
(1.42) | (1.37) | (1.16) | (2.38) | (2.29) | (1.77) | 2.13 | (3.14) | (4.93) | (5.26) |
Capex per Share |
(0.48) | (0.63) | (0.72) | (0.11) | (0.13) | (0.24) | (0.20) | (0.14) | (0.32) | (0.22) |
Free Cash Flow per Share |
(1.90) | (2.00) | (1.88) | (2.49) | (2.42) | (2.01) | 1.93 | (3.27) | (5.26) | (5.49) |
Cash per Share |
4.67 | 4.33 | 4.63 | 6.80 | 2.84 | 5.55 | 7.58 | 6.10 | 10.81 | 9.61 |
Shareholders Equity per Share |
3.84 | 3.13 | 3.51 | 2.19 | (1.18) | 1.87 | 3.91 | 2.32 | 2.88 | 2.49 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.84 | 3.13 | 3.51 | 2.19 | (1.18) | 1.87 | 3.91 | 2.32 | 2.88 | 2.49 |
Free Cash Flow |
(21.63) | (19.90) | (16.93) | (12.44) | (9.40) | (7.82) | 7.50 | (12.69) | (17.53) | (17.15) |
Working Capital |
34.26 | 25.62 | 31.57 | 33.78 | 4.23 | 17.93 | 25.26 | 27.82 | 36.09 | 28.23 |
Capital Expenditures |
(5.50) | (6.27) | (6.46) | (0.55) | (0.49) | (0.92) | (0.79) | (0.53) | (1.07) | (0.70) |
Net Current Asset Value |
17.34 | 9.82 | 14.83 | 6.74 | (9.37) | 2.40 | 10.21 | 6.41 | 7.01 | 5.62 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.33 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.32 | 0.31 | 0.35 | 0.02 | 0.02 | 0.04 | 0.02 | 0.16 | 0.43 | 0.45 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.76 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.10 | 0.10 | 0.14 | 0.54 | 0.50 | 0.41 | 0.50 | 0.29 | 0.29 | 0.46 |
Cash ROIC |
(22.35%) | (26.77%) | (23.09%) | (27.76%) | (145.50%) | (27.09%) | 16.80% | (38.91%) | (38.37%) | (45.36%) |
Accounts Receivable Turnover |
3.75 | 3.53 | 2.47 | 4.18 | 8.01 | 5.59 | 5.32 | 0.62 | 0.79 | 0.55 |
Accounts Payable Turnover |
2.12 | 3.25 | 2.70 | 2.58 | 3.90 | 4.03 | 3.49 | 0.70 | 0.48 | 0.97 |
Inventory Turnover |
4.04 | 6.35 | 6.28 | 8.43 | 11.62 | 9.50 | 7.20 | 1.17 | 1.16 | 1.69 |
Average Days of Payables |
203.69 | 109.60 | 133.55 | 154.86 | 114.26 | 76.81 | 125.28 | 474.60 | 751.97 | 561.54 |
Days of Inventory on Hand |
109.01 | 55.87 | 68.76 | 53.75 | 29.22 | 35.43 | 49.69 | 293.68 | 436.24 | 142.75 |
Average Receivables |
4.52 | 5.73 | 7.56 | 6.34 | 2.97 | 3.89 | 5.98 | 5.48 | 3.15 | 2.83 |
Average Payables |
6.46 | 5.40 | 5.59 | 5.17 | 3.84 | 3.53 | 3.39 | 2.98 | 3.29 | 2.22 |
Average Inventory |
3.39 | 2.77 | 2.40 | 1.58 | 1.29 | 1.50 | 1.65 | 1.78 | 1.37 | 1.28 |
Average Assets |
79.88 | 69.98 | 58.24 | 34.88 | 25.41 | 35.83 | 37.93 | 39.71 | 39.95 | 44.14 |
Average Common Equity |
37.39 | 31.37 | 21.25 | 3.17 | 1.35 | 11.22 | 12.07 | 9.30 | 8.70 | 15.62 |
Columns are period end dates